Diagnostics (Feb 2024)

EUS-Guided Gallbladder Drainage Using a Lumen-Apposing Metal Stent for Acute Cholecystitis: Results of a Nationwide Study with Long-Term Follow-Up

  • Cecilia Binda,
  • Andrea Anderloni,
  • Edoardo Forti,
  • Pietro Fusaroli,
  • Raffaele Macchiarelli,
  • Mauro Manno,
  • Alessandro Fugazza,
  • Alessandro Redaelli,
  • Giovanni Aragona,
  • Mauro Lovera,
  • Thomas Togliani,
  • Elia Armellini,
  • Arnaldo Amato,
  • Mario Luciano Brancaccio,
  • Roberta Badas,
  • Nicola Leone,
  • Germana de Nucci,
  • Benedetto Mangiavillano,
  • Monica Sbrancia,
  • Valeria Pollino,
  • Andrea Lisotti,
  • Marcello Maida,
  • Emanuele Sinagra,
  • Marco Ventimiglia,
  • Alessandro Repici,
  • Carlo Fabbri,
  • Ilaria Tarantino

DOI
https://doi.org/10.3390/diagnostics14040413
Journal volume & issue
Vol. 14, no. 4
p. 413

Abstract

Read online

Background: Although endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) has become one of the treatments of choice for acute cholecystitis (AC) in fragile patients, scant data are available on real-life settings and long-term outcomes. Methods: We performed a multicenter retrospective study including EUS-guided GBD using LAMS for AC in 19 Italian centers from June 2014 to July 2020. The primary outcomes were technical and clinical success, and the secondary outcomes were the rate of adverse events (AE) and long-term follow-up. Results: In total, 116 patients (48.3% female) were included, with a mean age of 82.7 ± 11 years. LAMS were placed, transgastric in 44.8% of cases, transduodenal in 53.3% and transjejunal in 1.7%, in patients with altered anatomy. Technical success was achieved in 94% and clinical success in 87.1% of cases. The mean follow-up was 309 days. AEs occurred in 12/116 pts (10.3%); 8/12 were intraprocedural, while 1 was classified as early (15 days). According to the ASGE lexicon, two (16.7%) were mild, three (25%) were moderate, and seven (58.3%) were severe. No fatal AEs occurred. In subgroup analysis of 40 patients with a follow-up longer than one year, no recurrence of AC was observed. Conclusions: EUS-GBD had high technical and clinical success rates, despite the non-negligible rate of AEs, thus representing an effective treatment option for fragile patients.

Keywords